Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
International Journal of Environmental Research and Public Health
|
April 12, 2022
Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients
Radu Vidra, Tudor Eliade Ciuleanu, Adina Nemeș, et al.
JAMA Network Open
|
August 18, 2022
Participation of Lower and Upper Middle-Income Countries in Clinical Trials Led by High-Income Countries
Fidel Rubagumya, Wilma M Hopman, Bishal Gyawali, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
October 22, 2018
Aberrant miRNAs expressed in HER-2 negative breast cancers patient
Cornelia Braicu, Lajos Raduly, Gabriela Morar-Bolba, et al.
The Oncologist
|
September 6, 2018
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe
Eduard Vrdoljak, Gyorgy Bodoky, Jacek Jassem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 23, 2018
Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning
Mursheda Begum, Grant Lewison, Jacek Jassem, et al.
Cancer
|
June 29, 2023
Allocation of authorship and patient enrollment among global clinical trials in oncology
Fidel Rubagumya, Adam Fundytus, Sophie Keith-Brown, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 5, 2023
European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care
Fatima Cardoso, Amelia McCartney, Antonio Ponti, et al.
The Oncologist
|
July 13, 2016
Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement
Eduard Vrdoljak, Gyorgy Bodoky, Jacek Jassem, et al.
The Lancet. Oncology
|
August 10, 2016
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Christoph Zielinski, István Láng, Moshe Inbar, et al.
The Lancet. Oncology
|
June 9, 2017
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial
Justin Stebbing, Yauheni Baranau, Valeriy Baryash, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
International Journal of Environmental Research and Public Health
|
April 12, 2022
Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients
Radu Vidra, Tudor Eliade Ciuleanu, Adina Nemeș, et al.
JAMA Network Open
|
August 18, 2022
Participation of Lower and Upper Middle-Income Countries in Clinical Trials Led by High-Income Countries
Fidel Rubagumya, Wilma M Hopman, Bishal Gyawali, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
October 22, 2018
Aberrant miRNAs expressed in HER-2 negative breast cancers patient
Cornelia Braicu, Lajos Raduly, Gabriela Morar-Bolba, et al.
The Oncologist
|
September 6, 2018
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe
Eduard Vrdoljak, Gyorgy Bodoky, Jacek Jassem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 23, 2018
Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning
Mursheda Begum, Grant Lewison, Jacek Jassem, et al.
Cancer
|
June 29, 2023
Allocation of authorship and patient enrollment among global clinical trials in oncology
Fidel Rubagumya, Adam Fundytus, Sophie Keith-Brown, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 5, 2023
European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care
Fatima Cardoso, Amelia McCartney, Antonio Ponti, et al.
The Oncologist
|
July 13, 2016
Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement
Eduard Vrdoljak, Gyorgy Bodoky, Jacek Jassem, et al.
The Lancet. Oncology
|
August 10, 2016
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Christoph Zielinski, István Láng, Moshe Inbar, et al.
The Lancet. Oncology
|
June 9, 2017
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial
Justin Stebbing, Yauheni Baranau, Valeriy Baryash, et al.
Page
of 7